aTYR PHARMA INC — Director's Dealing 2022

May 26, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2022-05-24

Reporting Person: DENYES NANCY (General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-24	Employee Stock Option (right to buy)	$2.81	A	88097	Acquired	2032-05-24	Common Stock (88097)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3447	Direct

Footnotes

F1: Includes 178 shares each acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on November 15, 2021 and May 13, 2022, respectively.

F2: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 24, 2022, such that this option will be fully exercisable on May 24, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.